Dextech Medical AB (XSAT:DEX)

Sweden flag Sweden · Delayed Price · Currency is SEK
11.30
0.00 (0.00%)
At close: Mar 3, 2026
186.80%
Market Cap 208.89M
Revenue (ttm) 3.07M
Net Income (ttm) -5.63M
Shares Out 18.49M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,472
Average Volume 9,949
Open 11.60
Previous Close 11.30
Day's Range 11.10 - 11.60
52-Week Range 3.62 - 14.40
Beta 1.51
RSI 55.60
Earnings Date Feb 25, 2026

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company’s lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors,... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2004
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol DEX
Full Company Profile

Financial Performance

In fiscal year 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.

Financial Statements

News

There is no news available yet.